Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies

Movement Disorders

Volumn 24, Issue 9, 2009, Pages 1319-1324

  LeWitt, Peter A ^a,e   Jennings, Danna ^b   Lyons, Kelly E ^c   Pahwa, Rajesh ^c   Rabinowickz, Adrian L ^d   Wang, James ^d   Guarnieri, Maria ^d   Hubble, Jean P ^d   Murck, Harold ^d  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Franklin Pointe Medical Center   (United States)

Author keywords

Entacapone; Levodopa; Motor fluctuation; Parkinson's disease; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; EVENING DOSAGE; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; PARKINSON DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; CARBIDOPA; CATECHOLS; CROSS-OVER STUDIES; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITRILES; PARKINSON DISEASE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 69549103564     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22587     Document Type: Article

References (19)

1. LeWitt P. The pharmacology of levodopa in treatment of Parkinson disease: an update. In: Calne D, editor. Drugs for the treatment of Parkinson's disease, Vol.88. Handbook of experimental pharmacology. Berlin: Springer-Verlag; 1989. p325-384.
2. Koller WC. Alternate day levodopa therapy in Parkinsonism. Neurology 1982;32:324-326.
3. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects requiring levodopa. Ann Neurol 1996;39:37-45.
4. Chan PL, Nutt JG, Holford NH. Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease. J Pharmacokinet Pharmacodyn 2005;32: 459-484.
5. Doller HJ, Connor JD. Changes in neostriatal dopamine concentrations in response to levodopa infusions. J Neurochem 1980;34: 1264-1269.
6. Zappia M, Bosco D, Plastino M, et al. Pharmacodynamics of the long-duration response to levodopa in PD. Neurology 1999;53: 557-560.
7. LeWitt PA, Nelson MV, Berchou RC, et al. Controlled-release carbidopa/ levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. Neurology 1989;39(suppl 2):45-53.
8. Cedarbaum JM, Hoey M, McDowell FH. A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance. J Neurol Neurosurg Psychiatry 1989;52:207-212.
9. Heikkinen H, Nutt JG, LeWitt PA, et al. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease. Clin Neuropharmacol 2001;24:150-157.
10. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden DM, Goldstein M, Calne DB, editors. Recent developments in Parkinson's disease, Vol.2. New York: MacMillan; 1987. p153-163.
11. Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23:75-81.
12. Nelson MV, Berchou RC, LeWitt PA, et al. Pharmacodynamic modeling of concentration-effect relationships after controlled-release carbidopa/ levodopa (Sinemet CR4) in Parkinson's disease. Neurology 1990;40:70-74.
13. Ahtila S, Kaakkola S, Gordin A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol 1995;18:46-57.
14. Müller T, Erdmann C, Muhlack S, et al. Pharmacokinetic behavior of levodopa and 3-O-methyldopa after repeat administration of levodopa/ carbidopa with and without entacapone in patients with Parkinson's disease. J Neural Transm 2006;113:1441-1448.
15. Merello M, Lees AJ, Webster R, et al. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:186-189.
16. Paija O, Laine K, Kultalahti ER, et al. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. Clin Neuropharmacol 2005;28:115-119.
17. Piccini P, Brooks DJ, Korpela K, et al. The catechol-Omethyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;68:589-594.
18. Müller T, Ander L, Kolf K, Woitalla D, Muhlack S. Comparison of 200 mg retarded release levodopa/carbidop - with 150 mg levodopa/carbidopa/ entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease. J Neural Transm 2007;114:1457-1462.
19. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.